If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
29 November Astronomers report the discovery of a star, HD 110067, that contains six sub-Neptune exoplanets with radii ranging from 1.94R⊕ to 2.85R⊕. The first example of a planet-forming disk beyond the Milky Way galaxy is reported by astronomers using the ALMA in Chile. The system, designated as HH 1177, is located in the Large Magellanic Cloud, about 160,000 light years away. 30 November Researchers demonstrate multicellular microbots grown from a human cell, "anthrobots", that can move around in tissues in vitro. A trial comparing a healthy vegan and a healthy omnivorous diet in identical twins finds the former to be substantially better according to cardiometabolic measures like LDL-C after 8 weeks. Promising innovations relating to global challenges are reported: an efficient electrocaloric heat pump for sustainable cooling (16 Nov), taste-tested bioreactor-grown cultured coffee (17 Nov), an autonomous laboratory for synthesis of inorganic powders, the A-Lab (29 Nov), a solar tower design using downdraft technology for hot and dry weather areas that could generate twice the electricity of solar updraft systems and operate at night, the Twin-Technology Solar System (TTSS) (30 Nov). Promising results of health and medical research are reported: phase 2-trialed Mazdutide against type-2 diabetes (9 Nov), phase 1-trialed lepodisiran against cardiovascular risk factor lipoprotein (12 Nov), rat-tested depot technology for sustained delivery of GLP-1 receptor agonists against the need for frequent injections (21 Nov).
==== Non-ionic ==== Non-ionic surfactants have covalently bonded oxygen-containing hydrophilic groups, which are bonded to hydrophobic parent structures. The water-solubility of the oxygen groups is the result of hydrogen bonding. Hydrogen bonding decreases with increasing temperature, and the water solubility of non-ionic surfactants therefore decreases with increasing temperature. Non-ionic surfactants are less sensitive to water hardness than anionic surfactants, and they foam less strongly. The differences between the individual types of non-ionic surfactants are slight, and the choice is primarily governed having regard to the costs of special properties (e.g., effectiveness and efficiency, toxicity, dermatological compatibility, biodegradability) or permission for use in food.
Ketamine's clinical and antidepressant effects can be influenced by co-administration of other drugs, though these interactions are variable and not yet fully understood. Ketamine was first synthesized in 1962; it was derived from phencyclidine in pursuit of a safer anesthetic with fewer hallucinogenic effects. It was approved for use in the United States in 1970. It has been regularly used in veterinary medicine and was extensively used for surgical anesthesia in the Vietnam War. It later gained prominence for its rapid antidepressant effects discovered in 2000, marking a major breakthrough in depression treatment. Racemic ketamine, especially at higher doses, may be more effective and longer-lasting than esketamine in reducing depression severity. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
=== Slaughter by the consumer === Insects may also be sold live for food purposes, and thus effectively slaughtered by the end human consumer prior to eating. Some "how to" guides for eating insects make no mention of freezing or other euthanasia methods. For example, Miles Olson's recommendations include:
=== Lifestyle === Counselling before pregnancy (for example, about preventive folic acid supplements) and multidisciplinary management are important for good pregnancy outcomes. Most women can manage their GDM with dietary changes and exercise. Self-monitoring of blood glucose levels can guide therapy. Some women will need antidiabetic drugs, most commonly insulin therapy. Any diet needs to provide sufficient calories for pregnancy, typically 2,000–2,500 kcal with the exclusion of simple carbohydrates. The main goal of dietary modifications is to avoid peaks in blood sugar levels. This can be done by spreading carbohydrate intake over meals and snacks throughout the day, and using slow-release carbohydrate sources—known as the G.I. Diet. Since insulin resistance is highest in the morning, breakfast carbohydrates must be restricted more. The Mediterranean diet may be associated with reduced incidence of gestational diabetes. However, there is not enough evidence to indicate if one type of dietary advice is better than another. Though there is no specific structure for exercise programs for GDM, it is understood that being subjected to constant exposure to a sedentary lifestyle and participating in <2999 MET-mins a week in physical activity is linked to a 10 times higher risk of developing GDM. Conversely, partaking in > 3000 MET-mins of any physical activity can reduce developing GDM.
Sources: en.wikipedia.org
Small copper carrier or SCC is a small molecule that transports copper in urine. It is excreted in the kidneys in humans or mice where the liver is unable to excrete excess copper in bile. This happens in Wilson's disease where the presence of copper in urine is a diagnostic. It was discovered by Lawrence Wilson Gray and Svetlana Lutsenko. The molecule is 2 kDa. Its exact nature is not yet known but is presumed to be a peptide. The same peptide also appears in blood and urine of many different mammals. Its copper free molecular weight is 1329.5. In neutral conditions the small copper carrier molecule has a negative charge. Copper is bound to the carrier via oxygen and nitrogen (O or N).
An estimated 90 percent of national Yemeni food consumption is dependent on imports, a factor that makes the country particularly vulnerable to trade disruptions, such as the one caused by the ongoing civil war. When trade flows were disrupted after 2015, this structural reliance rapidly translated into widespread food insecurity, with early UN assessments suggesting that two thirds of the population faced some degree of food shortage. Subsequent analyses describe a population increasingly reliant on food aid because of a combination of factors: the uncontrolled inflation, the prolonged suspension of many public-sector salaries, and the naval controls and port inspections imposed by the Saudi-led coalition, which slow and reduce imports through the main Red Sea ports, all are frequently cited as important factors to the economic stagnation. Between January and November 2020, the average cost of meeting food requirements was estimated to have risen by about 16 percent, making basic needs harder to afford even where these were still available. Humanitarian organisations and UN officials have repeatedly warned that all these dynamics are “starving” Yemen and have placed the country in a situation which the UN Secretary-General defined as the worst famine seen globally in decades.
Polyendocrine metabolic ovarian syndrome Polyendocrine metabolic ovarian syndrome + obesity + hirsutism + infertility Kallmann syndrome Aromatase excess syndrome Hypothalamic suppression Hypopituitarism Hyperprolactinemia Gonadotropin deficiency Gonadal suppression therapy GnRH antagonist GnRH agonist (downregulation). Isolated FSH deficiency due to mutations in the gene for β-subunit of FSH is rare with 13 cases reported in the literature up to 2019.
Ropinirole is metabolized primarily by cytochrome P450 CYP1A2 to form two metabolites; SK&F-104557 (N-Despropyl Ropinirole) and SK&F-89124, both of which are renally excreted, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24 mg, CYP2D6 may be inhibited, although this has been tested only in vitro. 7-Hydroxyropinirole (SK&F-89124), a major metabolite of ropinirole in rats but minor metabolite in humans (<5% of dose), is a highly potent dopamine receptor agonist with antiparkinsonian activity similarly to ropinirole. It has been reported to be 30-fold more potent than ropinirole as a dopamine D2 receptor agonist in vitro. However, ropinirole and 7-hydroxyropinirole were equipotent in terms of antiparkinsonian activity in rodents in vivo. 7-Hydroxyropinirole is said to be the only metabolite of ropinirole known to possess significant dopaminergic activity in vivo, although other ropinirole metabolites have also been found to have dopaminergic activity.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.